← Back to headlines
Bristol-Myers Squibb Raises 2026 Guidance, Milvexian AFib Readout Shifts
Bristol-Myers Squibb has increased its 2026 financial guidance, projecting 20-25% growth for Eliquis, while the readout for its milvexian AFib drug has been postponed to Q1 2027.
30 Jul, 19:25 — 30 Jul, 19:25
Sources
Showing 1 of 1 sources
Related Stories
Oldest Known Plague Outbreak Discovered in Siberia Dating Back 5,500 Years
just now
Thousands of New Cyclospora Cases Reported in US Outbreak
32m ago
Doctor warns about 5 'healthy' habits that can be harmful
33m ago
Doctor identifies daily habits as major factor in men's testosterone and erectile health
35m ago